Intravenous immunoglobulin therapy in COVID-19-related encephalopathy

Lorenzo Muccioli1 · Umberto Pensato1 · Giorgia Bernabè2 · Lorenzo Ferri1 · Maria Tappatà3 · Lilia Volpi3 · Ilaria Cani1 · Olivia J. Henry4 · Francesca Cecconari2 · Sabina Cevoli3 · Gloria Stofella3 · Elena Pasini3 · Giacomo Fornaro5 · Caterina Tonon1,3 · Simone Vidale2 · Rocco Liguori1,3 · Paolo Tinuper1,3 · Roberto Michelucci3 · Pietro Cortelli1,3 · Francesca Bisulli1,3

Received: 9 September 2020 / Revised: 17 September 2020 / Accepted: 19 September 2020 / Published online: 8 October 2020
© The Author(s) 2020

Abstract
Objective To report on efficacy and safety of intravenous immunoglobulin (IVIg) therapy in a case series of patients with COVID-19-related encephalopathy.
Methods We retrospectively collected data on all patients with COVID-19 hospitalized at two Italian hospitals who developed encephalopathy during disease course and were treated with IVIg.
Results Five patients (two females, mean age 66.8 years) developed encephalopathy after a mean of 12.6 days, since the onset of respiratory/constitutional symptoms related to COVID-19. Four patients suffered severe respiratory distress, three of which required invasive mechanical ventilation. Neurological manifestations included impaired consciousness, agitation, delirium, pyramidal and extrapyramidal signs. EEG demonstrated diffuse slowing in all patients. Brain MRI showed non-specific findings. CSF analysis revealed normal cell count and protein levels. In all subjects, RT-PCR for SARS-CoV-2 in CSF tested negative. IVIg at 0.4 g/kg/die was commenced 29.8 days (mean, range: 19–55 days) after encephalopathy onset, leading to complete electroclinical recovery in all patients, with an initial improvement of neuropsychiatric symptoms observed in 3.4 days (mean, range: 1–10 days). No adverse events related to IVIg were observed.
Conclusions Our preliminary findings suggest that IVIg may represent a safe and effective treatment for COVID-19-associated encephalopathy. Clinical efficacy may be driven by the anti-inflammatory action of IVIg, associated with its anti-cytokine qualities.

Introduction

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease-2019 (COVID-19). While many individuals with SARS-CoV-2 infection are asymptomatic or develop only mild respiratory and constitutional symptoms, a subgroup of patients present with complications, including acute respiratory distress syndrome, disseminated intravascular coagulation and multiorgan dysfunction syndrome [1, 2].

Cytokine release syndrome (CRS) is a systemic hyperinflammatory condition presenting secondary to monocyte, macrophage and dendritic cell activation in severe COVID-19 infection and has been implicated in disease pathophysiology [3].

Neuropsychiatric manifestations are increasingly being reported in association with COVID-19, including encephalopathy [4]. The pathophysiology underlying this
presentation remains unclear; however, a role of cytokine-mediated neuroinflammation has been suggested [5−10]. COVID-19-associated encephalopathy has been described responsive to high-dose steroids and plasmapheresis, consistent with an immune-mediated pathogenesis [5, 11, 12].

Intravenous immunoglobulin (IVIg) therapy has shown efficacy in treating systemic COVID-[13, 19] yet its role in the management of associated CNS manifestations remains to be determined.

We report five patients with COVID-19-related encephalopathy successfully treated with IVIg.

**Methods**

We retrospectively collected data on all patients with COVID-19 hospitalized at Bellaria Hospital, Bologna, and Infermi Hospital, Rimini, Italy, from March 13, 2020, to May 27, 2020, who developed encephalopathy during disease course and were treated with IVIg. COVID-19 diagnosis was made on the basis of at least one positive SARS-CoV-2 real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasopharyngeal swab specimens and consistent clinical and/or radiological findings. IVIg therapy was prescribed by the treating neurologist based on the patient’s clinical profile and suspected immune-mediated/inflammatory encephalopathy, in accordance with institutional and international guidelines.

**Results**

Five patients (two females) with a mean age of 66.8 years (range: 54−75 years) were included in this retrospective study. Demographics, comorbidities, disease course, timing of IVIg and other immunotherapies are summarized in Table 1. Clinical, neuroradiological, EEG and CSF findings are summarized in Table 2. The illustrative case of the first patient is shown in Fig. 1.

Three patients (1, 4, 5) were placed on invasive mechanical ventilation due to respiratory distress, while patient 2 was treated with non-invasive mechanical ventilation. Patient 3 had prior hospitalization in another facility for mild respiratory distress, where she was treated with low-flow oxygen therapy. She was subsequently re-admitted to our facility due to the subacute onset of neuropsychiatric symptoms. All patients developed encephalopathy, with a mean onset of 12.6 days (range 0−23 days) after the presentation of respiratory/constitutional symptoms related to SARS-CoV-2 infection. In patients 4 and 5, encephalopathy presented following sedation weaning as persisting impaired consciousness, whereas CNS symptoms developed in the other patients independently. Neurological manifestations were heterogeneous, including confusion, agitation, delirium, akinetic mutism, apraxia, pyramidal, extrapyramidal and frontal release signs. EEG demonstrated diffuse slowing in all patients, with frontal predominance in two cases. Brain MRI showed non-specific diffuse white-matter hyperintensities in two patients, while the others displayed chronic cerebrovascular findings.

### Table 1 Demographics, comorbidities and disease course

| Pt | Age (y), Sex | Comorbidities | COVID-19 onset (day)a,b | Worst P/F (day)a | IVIg treatment (0.4 g/kg/d) (start, end)a | Clinical Response (initial, complete)a | Other immunotherapies (start, end)a | Last f.up (day)a |
|----|------------|---------------|--------------------------|-----------------|------------------------------------------|---------------------------------------|----------------------------------|----------------|
| 1  | 54, F      | None          | − 5                      | 130 (+ 3)       | + 18, + 21                                | + 19, + 21                            | Tocilizumab 400 mg (+ 0)          | + 90           |
| 2  | 75, M      | Type 2 DM, hypertension, ischemic heart disease, previous stroke | 0               | 114 (+ 12)   | + 26, + 30                                | + 28, + 34                            | Tocilizumab 400 mg (+ 33) Low-dose steroids (+ 21, + 36) | + 115          |
| 3  | 69, F      | Bipolar disorder, MCI, iatrogenic parkinsonism, type 2 DM | − 15             | 345 (+ 14)   | + 28, + 32                                | + 30, + 38                            | MP 1 g/die (+ 13, + 17)           | + 86           |
| 4  | 69, M      | Hypertensive cardiopathy | − 23             | 81           | + 22, + 27                                | + 24, + 28                            |                                   | + 70           |
| 5  | 67, M      | Type 2 DM, hypertension | − 20             | 79           | + 55, + 60                                | + 65, + 75                            | Tocilizumab 400 mg + 105           |                |

DM diabetes mellitus, MCI mild cognitive impairment, MP methylprednisolone

aWe referred to encephalopathy onset as day “0”, and to all events occurred previously or subsequently as minus or plus “day”, respectively

bOnset of constitutional or respiratory symptoms such as fever, cough, dyspnea
Table 2 Neurological clinical and investigative findings

| Pt | Neurological manifestations                                                                 | EEG (D) | MRI (D) | CSF (D)                                                                  |
|----|--------------------------------------------------------------------------------------------|---------|---------|--------------------------------------------------------------------------|
| 1  | Irritability, quadriaparesis with pyramidal signs, akinetic mutism, agitated delirium, frontal release reflexes | Diffuse slowing at 6–7 Hz (+ 15) | Fronto-parietal white matter hyperintensity (+ 16) | Cells: 0/µL Proteins: 26 mg/dL Qalb: 4 (+ 17) |
| 2  | Confusion, disorientation, global memory deficits                                           | Diffuse slowing at 4–5 Hz (+ 21) | Previous right fronto-parietal stroke (+ 22) | Cells: 1 WBC/µL Proteins: 60 mg/dL Qalb: 17.8 (+ 25) |
| 3  | Apraxia, mixed delirium, pyramidal signs, frontal release reflexes, extrapyramidal signs (rigidity and bradykinesia) | Diffuse slowing at 6–7 Hz, frontal sharp waves (+ 13) | Parietal white matter hyperintensity, cerebral atrophy (+ 13) | Cells: 1 WBC/µL Proteins: 32 mg/dL Qalb: 3.8 (+ 9) |
| 4  | Decreased level of consciousness, agitation, tonic muscle spasms                           | Diffuse slowing at 5–6 Hz, FIRDA (+ 0) | Cerebral small vessel disease (chronic) (+ 2) | Cells: 6 WBC/µL Proteins 35 mg/dL (+ 1) |
| 5  | Decreased level of consciousness, agitation, hemiparesis with pyramidal signs, extrapyramidal signs (rigidity and tremor), frontal release reflexes | Diffuse slowing at 5–6 Hz (+ 2) | Cerebral small vessel disease (chronic) (+ 45) | Cells: 1 WBC/µL Proteins: 29 mg/dL (+ 2) |

*D number of days after encephalopathy onset, *FIRDA* frontal intermittent rhythmic delta activity, *Qalb* CSF/serum albumin quotient, *WBC* white blood cell

*a*Extrapyramidal signs were already present before COVID-19 due to drug-induced parkinsonism

---

Fig. 1 Disease course in patient 1. Neurological manifestations, respiratory distress, temperature, IL-6 levels, timing of immunomodulatory treatments and diagnostic investigations during disease course. Neurological status severity was evaluated by treating neurologists. On the 15th day after disease onset, neurological evaluation was performed during temporary weaning of sedatives (red dot). Temperature and SpO2/FiO2 ratio were measured at least daily during hospitalization. Crosses on the IL-6 line represent the actual measurements. EEG electroencephalography, EMG electromyography, ICU intensive care unit, IVIG intravenous immunoglobulin treatment, LP lumbar puncture, MRI magnetic resonance imaging, S/F SpO2/FiO2 ratio
Clinical course and investigative findings observed in the present case series, including negative RT-PCR for SARS-CoV-2 in CSF, absence of significant elevation of CSF cells and protein levels, non-specific MRI findings, and the dramatic response to immunotherapy, suggest an inflammatory/immune-mediated pathogenesis rather than CNS viral invasion. An autoantibody-mediated mechanism is unlikely to explain CNS involvement, based on the brief temporal interval between CNS and infection-related symptom onset, negative testing for anti-neuronal antibodies, and the prompt and sustained response to IVIg [15]. Cytokine-mediated neuroinflammation has been implicated in the underlying pathogenic mechanism of COVID-19-associated encephalopathy, and may have contributed to disease course in our patients [5–10]. Except the third case, all patients suffered acute respiratory distress secondary to CRS induced by SARS-CoV-2. Interestingly, case 3 is the only patient with previous cognitive impairment, a condition that possibly made her more susceptible to develop encephalopathy despite mild systemic inflammation, as in other reported geriatric patients [10]. In patient 1 and 4, we observed a delay between the rise of inflammatory markers in serum and the onset/peak of neurological manifestations, possibly due to a delayed rise of CSF cytokines with respect to serum levels. Unfortunately, we were not able to measure CSF cytokines.

IVIg has anti-cytokine qualities, which appear important for its anti-inflammatory action. This may be related to the presence of anti-cytokine autoantibodies found in natural human immunoglobulin, including anti-TNF-α, anti-IL-1 and anti IL-8 [18]. Additionally, the natural IgG fraction inhibits the production of proinflammatory cytokines in a dose-dependent manner via the Fc portion [18]. Accordingly, IVIg therapy has been shown to significantly reduce circulating proinflammatory cytokines within 3 days [19], as observed in patient 1.

Cytokines may drive neuroinflammation even without severe CRS, possibly as a consequence of local CNS production [5, 6, 20]. The IVIg anti-cytokine effects documented peripherally may independently and directly act on the CNS. IVIg can cross an intact blood–brain-barrier and is bioavailable in sufficient concentrations to interact with the therapeutic targets, with the maximum concentration reached in the CNS 24 h after administration in a murine model [1, 2].

None of our patients experienced adverse events related to IVIg. Adverse reactions to IVIg therapy are usually minor and occur in less than 10% of patients [15]. However, as both COVID-19 and IVIg may predispose to thromboembolic events such as stroke and pulmonary embolism [2, 15], prophylactic anticoagulation should be considered. In patients with evidence of coagulopathy, an alternate immunotherapy such as high-dose corticosteroids should be preferred. However, since the likelihood of thromboembolic disease in COVID-19 might be secondary to CRS, the global
thromboembolic risk may be partially compensated by the anti-inflammatory action of IVIg [1, 16].

**Conclusions**

IVIg was a safe and effective treatment for COVID-19-related encephalopathy in our case series. Clinical efficacy may be driven by the anti-inflammatory action of IVIg, associated with its anti-cytokine qualities. Our preliminary observation needs to be confirmed with larger clinical studies. However, considering the emerging evidence supporting an inflammatory-mediated pathogenesis in a subgroup of patients with COVID-19-related encephalopathy, we believe that immunotherapy with IVIg or other agents might be considered to hasten clinical recovery and prevent potential long-term neurological sequelae.

**Acknowledgements** We thank all the colleagues working at the COVID-19 units of Bellaria and Infermi hospitals, especially L. Guerra, S. Zaccaroni, L.L. Gramenegna, P. Riguzzi, C. Calabrò, E. Fileccia, G. Fornaro, F. Volpato, L. Bussini. We also thank Prof. R. Lodi, Prof. P. Alfanni, Prof. M.C. Re, G. Bordin, I. Bon, G. Rossini.

**Author contributions** LM, UP, GB and FB contributed to conception and design of the study; all authors contributed to the acquisition and/or analysis of data; LM and UP drafted the manuscript; IC prepared the figure; FB supervised the study.

**Funding** Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement.

**Compliance with ethical standards**

**Conflicts of interest** Nothing to report.

**Ethical approval** All investigations were carried out according to the Declaration of Helsinki.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382(18):1708–1720

2. Al-ANI F, Chehade S, Lazo-Langner A (2020) Thrombosis risk associated with COVID-19 infection. A scouting review. Thromb Res 192:152–160

3. Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science 368(6490):473–474

4. Koralnik IJ, Tyler KL (2020) COVID-19: a global threat to the nervous system. Ann Neurol 88(1):1–11

5. Pilotto A, Odolini S, Masciocchi S et al (2020) Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol. https://doi.org/10.1002/ana.25783

6. Muccioili L, Pensato U, Cani I et al (2020) COVID-19-associated encephalopathy and cytokine-mediated neuroinflammation. Ann Neurol. https://doi.org/10.1002/ana.25855

7. Cani I, Barone V, D’Angelo R et al (2020) Frontal encephalopathy related to hyperinflammation in COVID-19. J Neurol. https://doi.org/10.1007/s00415-020-10057-5

8. Farhadian S, Glick LR, Vogels CB et al (2020) Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurol 20(1):248. https://doi.org/10.1186/s12883-020-01812-2

9. Benameur K, Agarwal A, Auld SC et al (2020) Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. https://doi.org/10.3201/eid2609.201212

10. Beach SR, Praschan NC, Hogan C et al (2020) Delirium in COVID-19: a case series and exploration of potential mechanisms for central nervous system involvement. Gen Hosp Psychiatry 65:47–53

11. Pugin D, Vargas ML, Thieffry C et al (2020) COVID-19-related encephalopathy responsive to high doses glucocorticoids. Neurology. https://doi.org/10.1212/WNL.0000000000010354

12. Dogan L, Kaya D, Sarikaya T et al (2020) Plasmapheresis treatment in COVID-19-related autoimmune meningoencephalitis: case series. Brain Behav Immun 87:155–158

13. Cao W, Liu X, Bai T et al (2020) High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 7(3):102

14. Liu X, Cao W, Li T (2020) High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Front Immunol 11:1660. https://doi.org/10.3389/fimmu.2020.01660

15. Lünenmann JD, Nimmerjahn F, Dalakas MC (2015) Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nat Rev Neurol 11(2):80–89

16. Chaumont H, San-Galli A, Martino F et al (2020) Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. J Neurol. https://doi.org/10.1007/s00415-020-09986-y

17. Le Guennec L, Devianne J, Jalin L et al (2020) Orbitofrontal involvement in a neuroCOVID-19 patient. Epilepsia. https://doi.org/10.1111/epi.16612

18. Abe Y, Horiuichi A, Miyake M, Kimura S (1994) Anti-cytokine nature of a human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5–19

19. Sharief MK, Ingram DA, Swash M, Thompson EJ (1999) I.v. Immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 52(9):1833–1838

20. Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8(8):958–971

21. St-Amour I, Pare I, Alata W et al (2013) Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J Cereb Blood Flow Metab 33(12):1983–1992